Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Shares Outstanding (Weighted Average) (2016 - 2025)

Vanda Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 16 years, with the latest figure at $58.9 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 1.34% year-over-year to $58.9 million; the TTM value through Dec 2025 reached $58.9 million, up 1.34%, while the annual FY2025 figure was $58.9 million, 1.34% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $58.9 million at Vanda Pharmaceuticals, roughly flat from $59.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $59.1 million in Q3 2025 and bottomed at $55.1 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $57.3 million (2023), against an average of $57.2 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) grew 2.64% in 2021 before it increased 1.0% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $55.5 million in 2021, then rose by 1.64% to $56.5 million in 2022, then rose by 1.63% to $57.4 million in 2023, then grew by 1.34% to $58.1 million in 2024, then grew by 1.34% to $58.9 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Shares Outstanding (Weighted Average) are $58.9 million (Q4 2025), $59.1 million (Q3 2025), and $59.0 million (Q2 2025).